Pro-Dex

Q4 FY2026 EarningsFY26 beat consensus across all major top and bottom-line metrics, driven by a 30% YoY surge in Medical Device sales and one-time investment gains. Revenue reached $77.5M (+1.5% vs. $76.4M consensus), while Diluted GAAP EPS of $4.12 significantly outperformed the $3.94 estimate (+4.6%). A massive realized gain of $9.1M from the sale of Monogram Technologies offset increased G&A costs related to the APM acquisition, supporting a Bullish outlook as the core orthopedic segment transition accelerates.